New combo aims to outsmart recurrent breast cancer in phase 2 trial
Disease control
Not yet recruiting
This study tests whether a combination of fulvestrant and ribociclib works better than standard treatments for people with a certain type of advanced breast cancer (HR+, HER2-) that came back after they finished a previous targeted therapy. About 272 adults will be randomly assig…
Phase: PHASE2 • Sponsor: Yeon Hee Park • Aim: Disease control
Last updated May 12, 2026 13:39 UTC